Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671592 · ClinicalTrials.gov registry record · Phase 1
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
A Phase 1 study, sponsored by Pawel Kalinski.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01671592 is a Phase 1 study that has completed, run by Pawel Kalinski. The registered enrollment target is 6 participants.
The verdict
NCT01671592, a Phase 1 study, has completed, sponsored by Pawel Kalinski.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will evaluate the safety and feasibility MRI tracking of a vaccine produced from a persons cancer cells injected intradermally once a day for 3 consecutive days. One of the daily doses will contain a chemical that can be detected by an MRI. That will be either the 1st or 3rd day of the 3 day course. On that day MRI scans will be performed 6 and 24 hours after the injection on that day. Patients may be able to receive booster doses every 1-2 months
Interventions
- BIOLOGICAL DC Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671592
The ClinicalTrials.gov registry entry for NCT01671592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pawel Kalinski, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DC Vaccine is the first listed.
NCT01671592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01671592 about?
NCT01671592 is a clinical study titled "Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)". This study will evaluate the safety and feasibility MRI tracking of a vaccine produced from a persons cancer cells injected intradermally once a day for 3 consecutive days. One of the daily doses will contain a chemical that can be detected by an MRI. That will be either the 1st or 3rd day of the 3 ...
What is the current status of trial NCT01671592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01671592?
The interventions under investigation include: DC Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01671592?
This trial is sponsored by Pawel Kalinski, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.